A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women
- PMID: 21700360
- DOI: 10.1016/j.jaad.2010.09.724
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women
Abstract
Background: Although twice-daily application of propylene glycol-containing 2% minoxidil topical solution (MTS) stimulates new hair growth, higher concentrations of minoxidil in a once-daily, propylene glycol-free formulation may improve efficacy and reduce unpleasant side effects.
Objective: We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia.
Methods: A total of 113 women with androgenetic alopecia were randomized to 24 weeks of treatment with 5% MTF or 2% MTS. The primary efficacy parameter was change from baseline in nonvellus target area hair count at week 24. Secondary end points included change in nonvellus target area hair width, overall efficacy by global photographic review as assessed by treatment-blinded evaluators and the subject herself, adverse events, and participants' assessment of product aesthetics.
Results: After 24 weeks, women randomized to 5% MTF once daily showed noninferior target area hair count and target area hair width and experienced greater, but nonsignificant, improvements in target area hair count, target area hair width, and overall efficacy by global photographic review than those randomized to 2% MTS used twice daily. 5% MTF was significantly superior to 2% MTS in participants' agreement with "the treatment does not interfere with styling my hair" (P = .002). Women randomized to 5% MTF experienced significantly lower rates of local intolerance (P = .046) especially in pruritus and dandruff compared with 2% MTS.
Limitation: Because of differences in the formulations tested, study participants were not blinded to treatment.
Conclusions: Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Similar articles
-
A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.J Am Acad Dermatol. 2004 Apr;50(4):541-53. doi: 10.1016/j.jaad.2003.06.014. J Am Acad Dermatol. 2004. PMID: 15034503 Clinical Trial.
-
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.J Am Acad Dermatol. 2007 Nov;57(5):767-74. doi: 10.1016/j.jaad.2007.04.012. Epub 2007 Aug 29. J Am Acad Dermatol. 2007. PMID: 17761356 Clinical Trial.
-
Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.J Drugs Dermatol. 2016 Jul 1;15(7):883-9. J Drugs Dermatol. 2016. PMID: 27391640 Clinical Trial.
-
5% Minoxidil: treatment for female pattern hair loss.Skin Therapy Lett. 2014 Nov-Dec;19(6):5-7. Skin Therapy Lett. 2014. PMID: 25807073 Review.
-
Topical minoxidil therapy for hair regrowth.Clin Pharm. 1987 May;6(5):386-92. Clin Pharm. 1987. PMID: 3311578 Review.
Cited by
-
Quality by Design Perspective for Designing Foam-based Formulation: Current State of Art.Curr Pharm Des. 2024;30(6):410-419. doi: 10.2174/0113816128289965240123074111. Curr Pharm Des. 2024. PMID: 38747045 Review.
-
Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.JAMA Dermatol. 2024 Jun 1;160(6):600-605. doi: 10.1001/jamadermatol.2024.0284. JAMA Dermatol. 2024. PMID: 38598226 Clinical Trial.
-
Efficacy, Tolerability, and Superiority of Propylene Glycol-Free, North American Witch-Hazel (Hamamelis virginiana)-Based Solution of 5% Minoxidil Sulfate for the Treatment of Female Androgenetic Alopecia.Int J Trichology. 2023 May-Jun;15(3):108-112. doi: 10.4103/ijt.ijt_55_22. Epub 2023 Dec 1. Int J Trichology. 2023. PMID: 38179008 Free PMC article.
-
Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study).Cureus. 2023 Jul 11;15(7):e41681. doi: 10.7759/cureus.41681. eCollection 2023 Jul. Cureus. 2023. PMID: 37575862 Free PMC article.
-
Alopecia Areata: An Updated Review for 2023.J Cutan Med Surg. 2023 May-Jun;27(3):241-259. doi: 10.1177/12034754231168839. J Cutan Med Surg. 2023. PMID: 37340563 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous